(PDF) Intravitreal Ranibizumab as Primary Treatment for

Intravitreal Ranibizumab as Primary Treatment for Neovascular Membrane Associated With Idiopathic Juxtafoveal Retinal Telangiectasia

Graefe's Archive for Clinical and Experimental Ophthalmology - Germany

doi 10.1007/s00417-009-1117-3

Full Text

Abstract

Available in full text

Categories

Molecular Neuroscience

Sensory Systems

Date

June 16, 2009

Authors

Lazaros Konstantinidis

Leonidas Zografos

Publisher

Springer Science and Business Media LLC

Related search

Electrophysiologic Changes After Intravitreal Ranibizumab Injection for the Treatment of Choroidal Neovascular Membrane (CNVM)

Clinical Ophthalmology

English

Retinal Vascular Changes Following Intravitreal Ranibizumab Injections for Neovascular AMD Over a 1-Year Period

Sensory Systems

English

Intravitreal PRN Ranibizumab Treatment for Macular Edemadue to Branch Retinal Vein Occlusion

Turkish Journal of Medical Sciences

English

Effect of ARMS2 Gene Polymorphism on Intravitreal Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

Genetics and Molecular Research

Molecular Biology

English

Diffuse Retinal Thickening Due to Epiretinal Membrane in a Patient With Idiopathic Parafoveal Telangiectasia

Bezmialem Science

English

Intravitreal Ranibizumab, Photodynamic Therapy, and Vitreous Surgery for the Treatment of Juxtapapillary Retinal Capillary Hemangioma

Graefe's Archive for Clinical and Experimental Ophthalmology

Molecular Neuroscience

Sensory Systems

English

Neovascular Membranes Associated With Idiopathic Juxtafoveolar Telangiectasis

Archives of Ophthalmology

English

Intravitreal Ranibizumab for Diabetic Macular Edema With Prompt Versus Deferred Laser Treatment

English

Peripapillary Choroidal Thickness After Intravitreal Ranibizumab Injections in Eyes With Neovascular Age-Related Macular Degeneration

BMC Ophthalmology

English